Gladstone Institutional Advisory’s Sarepta Therapeutics SRPT Stock Holding History

Gladstone Institutional Advisory’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,885	Closed	-$302K	–	923
2026 Q1	$302K	Sell	13,885 -2,830	-17%	-$54.8K	0.01%	669
2025 Q4	$360K	Sell	16,715 -5,520	-25%	-$116K	0.01%	584
2025 Q3	$428K	Sell	22,235 -5,631	-20%	-$100K	0.02%	558
2025 Q2	$477K	Sell	27,866 -41,094	-60%	-$1.75M	0.02%	508
2025 Q1	$4.4M	Sell	68,960 -4,925	-7%	-$518K	0.21%	119
2024 Q4	$8.98M	Sell	73,885 -9,415	-11%	-$1.15M	0.42%	50
2024 Q3	$10.4M	Buy	83,300 +26,900	+48%	+$3.72M	0.51%	45
2024 Q2	$8.91M	Buy	56,400 +40	+0.1%	+$5.14K	0.46%	47
2024 Q1	$7.3M	Buy	+56,360	New	+$6.9M	0.4%	58
2021 Q4	–	Sell	-2,455	Closed	-$227K	–	632
2021 Q3	$227K	Buy	+2,455	New	+$189K	0.02%	489

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Gladstone Institutional Advisory's SRPT Position: Q2 2026 in Review

Gladstone Institutional Advisory sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 13,885 shares — an estimated $302K sold.

Gladstone Institutional Advisory first reported a position in SRPT in Q3 2021 and held it in 10 quarters. The position peaked at $10.4M in Q3 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Gladstone Institutional Advisory reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
Gladstone Institutional Advisory sold 13,885 Sarepta Therapeutics shares in Q2 2026, an estimated $302K.
Gladstone Institutional Advisory first reported a position in Sarepta Therapeutics in Q3 2021 and held it in 10 quarters.
Gladstone Institutional Advisory's Sarepta Therapeutics position peaked at $10.4M in Q3 2024.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.